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Abstract 
Neuropathic pain is pain arising from nerve damage to the conductive pathways of pain (ranging from 
nociceptors to post central gyrus). Neuropathic pain can be caused by 1) Carcinomas, 2) 
Trap/compressive, 3) Congenital, 4) Immunomediated, 5) Infection, 6) Metabolic disorders, 7) 
nutritional deficiency, 8) Toxin, 9) Lesion, 10) Vasculitis, 11). Connective tissue disorders. To date, the 
pathophysiology of neuropathic pain can not be explained thoroughly, this problem leads to the 
treatment which has not given satisfactory results as expected. There are many types of drugs has 
been used for the treatment of neuropathic pain, and they are generally aimed to stop the flow of 
impulses in the nervous system which was activated as a result of ectopic generators in areas 
experiencing nerve injury. These drugs work in several locations such as: drugs that works on 'sodium 
channel  voltage  gate'  (i.e  Carbamazepine  group),  drugs  that  works  on  'calcium  channel'  (i.e 
Gabapentin and Pregabalin), and also drugs that works on ‘the synapses gap’ (i.e Tricyclic class). 
Besides drugs that inhibit pain impulses propagation, the treatment of neuropathic pain also include 
drugs that have the ability of nervous system regeneration such as methylcobalamin group. The 
rationale of the use of this kind of drugs is that this drug expected to regenerate the damage of the 
nervous system damage which is lead to decrease the ectopic generator activity, the end result is the 
reducement of neuropathic pain experienced by patients. 
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Introduction 
Neuropathic pain is common, greatly impairs quality of life and has a high economic impact on 
society: the Institute of Medicine reports that at least 116 million American adults suffer from chronic 
pain, and estimates for people suffering from neuropathic pain are as high as 17.9%. Co-morbidities 
such as poor sleep, depression and anxiety are common in neuropathic pain patients, leading to 
unresolved arguments about whether pain causes mood and sleep changes or whether individuals with 
mood and sleep disorders are at a higher risk of developing pain (Hehn et al., 2012). Neuropathic pain 
(NP) is estimated to afflict as high as 7–8% of the general population in Europe (Attal et al., 2010), an 
estimated prevalence of 5% to 7% in France, compared with 20% to 31% for chronic pain (Delorme 
et al., 2011) and It is a common condition with an overall prevalence between 0.9 and 8.0% 
(Athanasakis et al., 2013). 
 
The International Association for the Study of Pain (IASP) defines neuropathic pain (NP) as pain 
‘‘initiated or caused by a primary lesion or dysfunction in the nervous system’’. It is estimated to afflict 
millions of people worldwide, although precise figures are not available. Neuropathic pain can be 
caused by a number of different diseases (e.g., diabetes mellitus, herpes zoster, human 
immunodeficiency virus [HIV] infection), medical interventions (e.g., chemotherapy, surgery), and 
injuries (e.g., brachial plexus avulsion) cause NP by producing lesions in somatosensory pathways in 
the peripheral or central nervous system (Dworkin et al., 2007; O’Connor & Dworkin, 2009). The 
management of patients with NP is complex and response to existing treatments is often inadequate. 
Even with well-established NP medications, effectiveness is unpredictable, dosing can be complicated, 
analgesic onset is delayed, and side effects are Common (Dworkin et al., 2007; Attal et al., 2010). 
 
Materials and Methods 
This article review form articles related with the pharmacologic aspect of  neuropathic pain. All data 
contained in this article is the result of a number of articles search. 
 
Results and Discussion 
In 2006, the European Federation of Neurological Societies (EFNS) produced the first guidelines on 
pharmacological treatment of NP. Since 2006, new randomized controlled trials (RCTs) have appeared 
in various NP conditions, justifying an update (Dworkin et al., 2007; Attal et al., 2010). 
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Pharmacological treatment is the mainstream in post-herpetic neuralgia (PHN), diabetic peripheral 
neuropathic pain (DPNP), central post-stroke pain (CPSP), trigeminal neuralgia (TN), complex regional 
pain syndrome (CRPS), cancer pain, failed back syndrome etc, while polypharmacy is still the major 
prescriptions facing such kind of miserable patients. The tricyclic antidepressants (TCA), gamma- 
aminobutyric acid (GABA), voltage-dependent calcium channel blockers, selective non-epinephrine 
reuptake inhibitor (SNRI), opioid or morphine etc, are still evidence-based medicines (EBM) but with 
different outcome for individuals (Yang et al., 2012). Use of antiepileptics with demonstrated efficacy 
as first-line therapy has increased in neuropathic pain (Hall et al., 2013). 
 
Table 1. Stepwise Pharmacologic Management of Neuropathic Pain (O’Connor & Dworkin, 2009)   
Step 1 
     Assess pain and establish the diagnosis of NP, if uncertain about the diagnosis, refer to a 
pain specialist or neurologist 
     Establish and treat the cause of NP; if uncertain about availability of treatment addressing 
NP etiology, refer to appropriate specialist 
 Identify relevant comorbidities (e.g., cardiac, renal, or hepatic disease, depression, gait 
instability) that might be relieved or exacerbated by NP treatment, or that might require 
dosage adjustment or additional monitoring of therapy 
     Explain the diagnosis and treatment plan to the patient, and establish realistic expectations 
Step 2 
     Initiate therapy of the disease causing NP, if applicable 
     Initiate symptom treatment with one or more of the following: 
   Antideppresant medication: either secondary amine TCA (nortriptyline, desipramin) or 
SSNRI (duloxetine, venlafaxine) 
   Calsium channel α2-δ ligand: either gabapentin or pregabalin 
   For patients with localized peripheral NP: topical lidocaine used alone or in combination 
with 1 of the other first-line therapies 
   For patients with acute NP, neuropathic cancer pain, or episodic exacerbations of 
severe pain, and when prompt pain relief during titration of a first-line medication to an 
efficacious dosage is required, opioid analgesics or tramadol may be used alone or in 
combination with 1 of the first-line therapies. 
     Evaluate patient for nonpharmacologic treatments, and initiate if appropriate 
Step 3 
     Reassess pain and health-related quality of life frequently 
 If substantial pain relief (e.g., average pain reduced to NRS ≤3/10) and tolerable side 
effects, continue treatment. 
 If partial pain relief (e.g., average pain remains ≥4/10) after an adequate trial, add 1 of the 
other first-line medications 
 If no or inadequate pain relief (e.g., <30% reduction) at target dosage after an adequate 
trial, switch to an alternative first-line medication 
Step 4 
     If  trials  of  first-line  medications  alone  and  in  combination  fail,  consider  second-line 
             medications or referral to a pain specialist or multidisciplinary pain Center   
NP-neuropathic  pain;  NRS-numeric  rating  scale;  SSNRI-selective  serotonin  and  norepinephrin 
  reuptake inhibitor; TCA-tricyclic antidepressant. Reprinted with permission from Pain.   
 
Three classes of medications were recommended as firstline treatments: antidepressants with both 
norepinephrine and serotonin reuptake inhibition (TCAs and selective serotonin and norepinephrine 
reuptake inhibitors [SSNRIs]), calcium channel 2- ligands (gabapentin and pregabalin), and topical 
lidocaine (lidocaine patch 5%). Opioids and tramadol were recommended as generally second-line 
treatments, except in certain specific clinical situations in which it was recommended that first-line use 
could  be  considered.  A  number  of  medications  were  considered  third-line  choices  (O’Connor  & 
Dworkin, 2009). Based on efficacy and safety, pregabalin is considered a first-line drug together with 
gabapentin in the treatment of central pain (Finnerup & Jensen, 2007). 
 
The guidelines acknowledge that a combination of medications with efficacy for neuropathic pain may 
provide greater analgesia than use of individual medications as monotherapy, although such 
combination therapy will often be associated with increased side effects, inconvenience, risk of drug 
interactions, and cost. Nevertheless, because 50% of patients in Neuropathic Pain trials of efficacious 
medications typically achieve satisfactory pain relief, many patients in clinical practice will require 
treatment with a combination of medications. Such combination therapy was incorporated into a 
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stepwise  management  strategy  for  patients  with  partial  responses  to  treatment  with  first-line 
medications (O’Connor & Dworkin, 2009). 
 
Table 2. Summary of the results of Randomized Clinical Trials Involving First and Second-Line 
   Medications for Patients With Neuropathic Pain (O’Connor & Dworkin, 2009)                     
 
TCA Dul     Venl    Gaba Preg Topical Opioid  Tra 
 oxet   afaxi   pen aba lidocaine analges  ma 
 
Peripheral NP 
            ine      ne       tin        lin        patch 5%      ic             dol   
-      Painful DPN 
-      PHN 
-      Painful polyneuropathy 
-      Phantom limb pain 
-      Postmastectomy pain 
-      GBS 
-      Neuropathic cancer pain 
-      CPRS type I 
-      Chronic lumbal root pain 
- Chemotherapy         induced 
neuropathy 
-      HIV Neuropathy 
Central NP 
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The NeuPSIG guidelines note that few medications have been found to be efficacious in neuropathic 
pain originating from a lesion in the central nervous system. RCTs have demonstrated efficacy for 
TCAs in central poststroke pain, and for calcium channel _2-_ ligands in spinal cord injury and 
poststroke central neuropathic pain. The Canadian Pain Society created 4 levels of recommendation, 
with first- and second-line medications differentiated by “the quality of evidence and the evidence of 
efficacy” based on NNTs. Medications were classified as third-line treatments if they have good 
evidence of efficacy, but require specialized monitoring and follow-up not required of drugs at the 
other levels. Fourth-line medications were described as having “at least 1 positive RCT, but required 
further study” (O’Connor & Dworkin, 2009). 
 
As with the NeuPSIG and Canadian Pain Society guidelines, the EFNS guidelines grade the level of 
evidence for different available treatments. However, unlike the other 2 sets of guidelines, separate 
recommendations were made for the treatment of patients with painful polyneuropathies (including 
painful  diabetic  peripheral  neuropathy), postherpetic neuralgia, trigeminal  neuralgia, and  central 
neuropathic pain. Consistent with the NeuPSIG and Canadian Pain Society guidelines, the EFNS 
guidelines recommended gabapentin, pregabalin, and TCAs as first-line treatments for painful 
polyneuropathies, postherpetic neuralgia, and central neuropathic pain (Moulin et al., 2007; O’Connor 
& Dworkin, 2009; Rhodes, 2011). 
 
Table 3. Comparison of Neuropathic Pain Treatment Guidelines, Excluding Trigeminal Neuralgia 
(O’Connor & Dworkin, 2009). 
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Other  EFNS  recommendations  for  painful  polyneuropathies  were  duloxetine  and  venlafaxine  as 
second-line treatment (“because of moderate efficacy”), and opioids, tramadol, and lamotrigine as 
“second-/thirdline therapy.” Additional recommendations for postherpetic neuralgia were topical 
lidocaine as a first-line treatment for patients with localized pain and allodynia, and opioids, tramadol, 
capsaicin, and valproic acid as second-line treatment options. “Second-/third-line” treatment options 
for patients with central neuropathic pain were lamotrigine, opioids, and cannabinoids (Moulin et al., 
2007; O’Connor & Dworkin, 2009; Rhodes, 2011). 
 
Two drugs have been approved for neuropathic pain in the US – pregabalin and duloxetine – but 
neither of these afford complete relief, even when used in combination (Vinik & Cassellini, 2012). In 
addition, several novel drug treatments such as botulinum toxin, capsaicin patch and lacosamide have 
been also used for neuropathic pain therapy. Table 5 summarizes the major pharmacological 
treatments for neuropathic pain and their analgesia mechanisms (Xu et al., 2012). 
 
Table 4. Major pharmacological treatment for neuropathic pain and their basic mechanisms (Xu et al., 
  2012)   
                   Compound                                                                  Mode of action   
Antidepressant 
-       Nortriptiline 
-       Desipramine 
-       Duloxetine 
-       Venlafaxine 
Anticonvulsants 
-       Gabapentin 
 
-       Pregabalin 
 
-       Lacosamide 
 
Opioid agonists 
-       Morphine 
-       Oxycodon 
-       Methadone 
-       Levorphanol 
-       Tramadol 
Topical therapy 
-       5% lidocaine patch 
-       High dose capsaicin patch 
-       Botulinum toxin 
Inhibition of both serotonin and norepinephrine reuptake 
Inhibition of both serotonin and norepinephrine reuptake 
Inhibition of both serotonin and norepinephrine reuptake Inhibition of both 
serotonin and norepinephrine reuptake 
 
Decreases  release  of  glutamate,  norepinephrine  and  substance  P,  with 
ligands on α2-δ subunit of voltage 
Decreases  release  of  glutamate,  norepinephrine  and  substance  P,  with 
ligands on α2-δ subunit of voltage 





μ-receptor agonism, κ-receptor antagonism 
μ-receptor agonism 
μ-receptor agonism, inhibition of norepinephrine and serotonin reuptake 
 
Block of sodium channel 
Damage of nociceptive sensory axons, a highly selective activating ligand 
for TRPV1 
Inhibition  of  both  the  exocytosis  of  acetylcholine  and  some  other 
                                                         neurotransmitter   
 
Pregabalin reduces the enhanced noxious stimulus-induced spinal release of glutamate seen in 
neuropathic rats (Kumar et al., 2010). Intranasal or intrathecal pregabalin relieves neuropathic pain 
behaviours, perhaps due to pregabalin’s effect upon anterograde CaVa2δ-1 protein trafficking from the 
DRG to the dorsal horn. Intranasal delivery of agents such as pregabalin may be an attractive 
alternative to systemic therapy for management of neuropathic pain states (Martinez et al., 2012). 
The anti-allodynic effects of gabapentin may be caused by upregulation of IL-10 expression in the 
spinal cord, which leads to inhibition of the expression of pro-inflammatory cytokines in the spinal 
cords (Lee et al., 2013). 
 
Capsaicin is a transient receptor potential vanilloid-1 agonist, which increases the intracellular calcium 
ion concentration. This triggers calcium-dependent protease enzymes causing cytoskeletal breakdown 
and leads to the loss of cellular integrity and ‘defunctionalization’ of nociceptor fibres. Efficacy and 
therapeutic effect has been shown in several clinical studies of PHN and HIV-DSP. The high- 
concentration  capsaicin  patch  and  its  practical  application  are  different  from  low-concentration 
creams; one application can help for up to 3 months (Irving et al., 2011; Webster et al., 2012; 
Baranidharan  et  al.,  2013).  A  single  30-minute  application  of  NGX-4010  (Capsaicin  8%  patch) 
provides significant pain relief for at least 12 weeks in patients with HIV-DSP and is well tolerated 
(Simpson et al., 2008; Brown et al., 2013). 
 
Activation of TRPV1 by capsaicin results in sensory neuronal depolarization, and can induce local 
sensitization to activation by heat, acidosis, and endogenous agonists. Topical exposure to capsaicin 
leads to the sensations of heat, burning, stinging, or itching. High concentrations of capsaicin or 
repeated applications can produce a persistent local effect on cutaneous nociceptors, which is best 
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described  as  defunctionalization and  constituted  by reduced  spontaneous  activity and  a  loss of 
responsiveness to a wide range of sensory stimuli (Anand & Bley, 2011; Bley, 2013). 
 
Conclusions 
All guidelines recommend TCAs, gabapentin, and pregabalin as first-line treatment options for patients 
with  neuropathic  pain  (excluding  trigeminal  neuralgia).  The  NeuPSIG  guidelines  recommend 
duloxetine and venlafaxine as first-line treatment options, but the Canadian Pain Society and EFNS 
guidelines recommend these SSNRIs as second-line options for patients with painful polyneuropathies. 
Clinicians  need  to  consider  the  advantage  and  disadvantage  of  these  managements  to  avoid 
ineffective treatments, maximize curing proven beneficial in clinical trials, and minimize the side effect 
of therapies. To improve the current management of patients with neuropathic pain, evidence-based 
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